On Friday 1 September, the European Commission authorised the Covid-19 vaccine adapted to Comirnaty XBB.1.5, developed by BioNTech-Pfizer.
This vaccine, which targets the Omicron XBB.1.5 sub-variant, marks an important new step in the fight against the disease. This is the third adaptation of this vaccine to respond to new Covid-19 variants.
The vaccine has been approved for adults, children and infants aged over six months. In line with previous recommendations from the European Medicines...